Dextech Medical Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Dextech Medical hat ein Gesamteigenkapital von SEK28.5M und eine Gesamtverschuldung von SEK0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen SEK29.2M bzw. SEK687.0K.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

SEK 0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	SEK 17.99m
Eigenkapital	SEK 28.47m
Gesamtverbindlichkeiten	SEK 687.00k
Gesamtvermögen	SEK 29.16m

Jüngste Berichte zur Finanzlage

Recent updates

Dextech Medical (NGM:DEX) Is In A Good Position To Deliver On Growth Plans

Jan 10

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

Sep 20

We're Not Very Worried About Dextech Medical's (NGM:DEX) Cash Burn Rate

Jun 03

What Kind Of Shareholders Hold The Majority In Dextech Medical AB's (NGM:DEX) Shares?

Feb 17

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

Dec 12

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: DEXDie kurzfristigen Aktiva des Unternehmens (SEK18.6M) übersteigen seine kurzfristigen Passiva (SEK687.0K).

Langfristige Verbindlichkeiten: DEX hat keine langfristigen Verbindlichkeiten.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: DEX ist schuldenfrei.

Schulden abbauen: DEX hat in den letzten 5 Jahren keine Schulden gemacht.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: DEX auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: DEX über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt, wenn der freie Cashflow weiterhin mit historischen Raten von 4.8% pro Jahr zurückgeht

Dextech Medical Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Dextech Medical (NGM:DEX) Is In A Good Position To Deliver On Growth Plans

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

We're Not Very Worried About Dextech Medical's (NGM:DEX) Cash Burn Rate

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

Recent updates

First quarter 2025 earnings released: kr0.062 loss per share (vs kr0.05 loss in 1Q 2024)

Dextech Medical AB to Report First Half, 2025 Results on Feb 27, 2025

Dextech Medical AB to Report Q1, 2025 Results on Oct 24, 2024

Dextech Medical AB Announces Continued Positive Results from Myeloma Study

Third quarter 2024 earnings released: kr0.077 loss per share (vs kr0.079 loss in 3Q 2023)

DexTech Medical Announces New Positive Results from the Myeloma Study

New major risk - Market cap size

Second quarter 2024 earnings released: kr0.058 loss per share (vs kr0.065 loss in 2Q 2023)

New major risk - Share price stability

Dextech Medical AB Announces Positive Results from the Myeloma Study

DexTech Medical Informs About the Myeloma Study, the First Patient Is Treated

First quarter 2024 earnings released: kr0.05 loss per share (vs kr0.044 loss in 1Q 2023)

Dextech Medical AB, Annual General Meeting, Oct 31, 2023

Full year 2023 earnings released: kr0.25 loss per share (vs kr0.31 loss in FY 2022)

New minor risk - Share price stability

Third quarter 2023 earnings released: kr0.079 loss per share (vs kr0.061 loss in 3Q 2022)

Second quarter 2023 earnings released: kr0.065 loss per share (vs kr0.076 loss in 2Q 2022)

Dextech Medical AB to Report Fiscal Year 2024 Results on Aug 30, 2024

No independent directors

First quarter 2023 earnings released: kr0.044 loss per share (vs kr0.063 loss in 1Q 2022)

Dextech Medical AB Announces Upcoming Multiple Myeloma Study

Full year 2022 earnings released: kr0.31 loss per share (vs kr0.41 loss in FY 2021)

Dextech Medical AB to Report Q1, 2023 Results on Oct 27, 2022

Dextech Medical AB Announces Application Approval for Myeloma Study from Medical Products Agency

Dextech Medical AB Appoints Andreas Segerros as A New Ordinary Board Member

Third quarter 2022 earnings released: kr0.061 loss per share (vs kr0.10 loss in 3Q 2021)

No independent directors

DexTech Medical to Soon Advance into the Clinical Phase in Multiple Myeloma with the Main Candidate OsteoDex

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Dextech Medical (NGM:DEX) Is In A Good Position To Deliver On Growth Plans

Full year 2021 earnings released: kr0.41 loss per share (vs kr0.52 loss in FY 2020)

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

Full year 2021 earnings released: kr0.41 loss per share (vs kr0.52 loss in FY 2020)

DexTech Medical AB Plans New Clinical Study on Multiple Myeloma

We're Not Very Worried About Dextech Medical's (NGM:DEX) Cash Burn Rate

DexTech Medical AB Confirms Very Positive Results from Myeloma Studies

Third quarter 2021 earnings released: kr0.10 loss per share (vs kr0.13 loss in 3Q 2020)

What Kind Of Shareholders Hold The Majority In Dextech Medical AB's (NGM:DEX) Shares?

New 90-day high: kr59.40

Second quarter 2021 earnings released: kr0.10 loss per share (vs kr0.13 loss in 2Q 2020)

DexTech Medical AB Receives Positive Results Regarding Multiple Myeloma

New 90-day low: kr45.20

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

First quarter earnings released

Full year earnings released - kr0.52 loss per share

Full year earnings released - kr0.52 loss per share

New 90-day low - kr38.00

New 90-day low - kr42.00

New 90-day low - kr45.00

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen